囊性纤维化
遗传增强
基因组编辑
疾病
医学
基因
基因传递
生物信息学
计算生物学
基因组
生物
遗传学
病理
内科学
标识
DOI:10.2174/1566523222666220720102556
摘要
Like any inherited protein deficiency disease, cystic fibrosis (CF) is a good candidate for gene replacement therapy. Despite the tremendous efforts of scientists worldwide invested in developing this approach, it did not lead to the expected results for various reasons discussed in this review. At the same time, the emergence of new methods of genome editing, as well as their latest modifications, makes it possible to bypass some of the problems of "classical" CF gene therapy. The review examines potential therapeutic agents for CF gene therapy, methods and routes of delivery, as well as discusses the problem of target cells for defect correction. Based on the results of these studies, editing genetic defects in the basal cells of the lungs and their counterparts in other organs will make it possible to create a drug for treating CF with a single administration.
科研通智能强力驱动
Strongly Powered by AbleSci AI